Nippon Chemi-Con Corporation
Nippon Chemi-Con Corporation (6997.T) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Nippon Chemi-Con Corporation (6997.T), covering cash flow, earnings, and balance sheets.
Nippon Chemi-Con Corporation (6997.T) Income Statement & Financial Overview
Review Nippon Chemi-Con Corporation 6997.T income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $31.86B | $30.91B | $30.62B | $29.30B |
| Cost of Revenue | $25.96B | $25.22B | $24.24B | $23.54B |
| Gross Profit | $5.90B | $5.69B | $6.38B | $5.76B |
| Gross Profit Ratio | $0.19 | $0.18 | $0.21 | $0.20 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $4.45B | $5.25B | $5.05B | $5.24B |
| Operating Expenses | $4.45B | $5.25B | $5.05B | $5.24B |
| Total Costs & Expenses | $30.41B | $30.48B | $29.29B | $28.78B |
| Interest Income | $32.00M | $52.00M | $57.00M | $36.00M |
| Interest Expense | $683.00M | $511.00M | $750.00M | $437.00M |
| Depreciation & Amortization | $1.83B | $1.69B | $1.80B | $1.70B |
| EBITDA | $2.88B | $2.13B | $2.33B | $2.21B |
| EBITDA Ratio | $0.09 | $0.07 | $0.08 | $0.08 |
| Operating Income | $1.45B | $437.00M | $1.33B | $520.00M |
| Operating Income Ratio | $0.05 | $0.01 | $0.04 | $0.02 |
| Other Income/Expenses (Net) | -$1.09B | -$524.00M | -$1.55B | -$10.00M |
| Income Before Tax | $363.00M | -$87.00M | -$223.00M | $510.00M |
| Income Before Tax Ratio | $0.01 | -$0.003 | -$0.007 | $0.02 |
| Income Tax Expense | $320.00M | -$29.00M | $147.00M | $60.00M |
| Net Income | $23.00M | -$64.00M | -$372.00M | $451.00M |
| Net Income Ratio | $0.001 | -$0.002 | -$0.01 | $0.02 |
| EPS | $1.12 | -$3.04 | -$17.46 | $21.12 |
| Diluted EPS | $0.61 | -$3.04 | -$17.46 | $13.99 |
| Weighted Avg Shares Outstanding | $21.35M | $21.36M | $21.36M | $21.36M |
| Weighted Avg Shares Outstanding (Diluted) | $21.36M | $21.36M | $21.36M | $21.02M |
The company's financials show resilient growth, with revenue advancing from $29.30B in Q1 2024 to $31.86B in Q4 2024. Gross profit remained healthy with margins at 19% in Q4 2024 compared to 20% in Q1 2024. Operating income hit $1.45B last quarter, sustaining a consistent 5% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $2.88B. Net income rose to $23.00M, while earnings per share reached $1.12. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan